| Year |
Citation |
Score |
| 2020 |
Khan Z, Di Nucci F, Kwan A, Hammer C, Mariathasan S, Rouilly V, Carroll J, Fontes M, Ley Acosta S, Guardino E, Chen-Harris H, Bhangale T, Mellman I, Rosenberg J, Powles T, et al. Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 32430334 DOI: 10.1073/Pnas.1922867117 |
0.349 |
|
| 2020 |
Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, Heath EI, Merchan J, Quinn DI, Srinivas S, Milowsky M, et al. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902044. PMID 32031899 DOI: 10.1200/Jco.19.02044 |
0.308 |
|
| 2020 |
Petrylak D, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Bertrandt AM, Powles T. Abstract B26: EV-301: A phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Bladder19-B26 |
0.382 |
|
| 2020 |
Telis L, Clinton T, Almassi N, Teo MY, Funt S, Donahue T, Schultz N, Berger M, Al-Ahmadie H, Solit D, Bajorin D, Rosenberg J, Dalbagni G, Bochner B, Iyer G, et al. Pd47-02 “Actionable” Genomic Alterations In Chemotherapy Resistant Muscle-Invasive Bladder Cancer The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000934.02 |
0.38 |
|
| 2020 |
Almassi N, Easthausen I, Ghafoor S, Christos P, Donahue T, Rosenberg J, Farooki A. Mp55-16 Skeletal-Related Events In Patients With Bone-Metastatic Carcinoma Of The Bladder Or Upper Urinary Tract The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000924.016 |
0.305 |
|
| 2020 |
Clinton T, Wise H, Almassi N, Chavan S, Hu W, Dason S, Pietzak E, Cha E, Dalbagni G, Iyer G, Bochner B, Rosenberg J, Bajorin D, Arcila M, Al-Ahmadie H, et al. Pd42-06 Defining The Genetic Evolution Of Epigenetic Alterations In Bladder Cancer The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000922.06 |
0.332 |
|
| 2020 |
Tracey A, Wong N, Clinton T, Rosenberg J, Iyer G, Solit D, Coleman J. Pd18-10 Identifying The Frequency Of Actionable Genomic Alterations In Localized And Metastatic Upper Tract Urothelial Carcinoma The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000861.010 |
0.327 |
|
| 2020 |
Pietzak* E, Carlo M, Srinivasan P, Bandlamudi C, Joseph V, Walasek A, Clinton T, Almassi N, Wiseman M, Khurram A, Bagrodia A, Cha E, Mandelker D, Kemel Y, Zhang L, ... ... Rosenberg J, et al. PD12-09 INHERITED CANCER PREDISPOSITION GENE VARIANTS IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER The Journal of Urology. 203: e262-e263. DOI: 10.1097/Ju.0000000000000846.09 |
0.398 |
|
| 2019 |
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, ... ... Rosenberg J, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics. PMID 30643254 DOI: 10.1038/S41588-018-0312-8 |
0.42 |
|
| 2019 |
Luksza M, Solovyov A, Vabret N, Balachandran V, Riaz N, Makarov V, Hellmann MD, Snyder A, Funt S, Remark R, Merad M, Gnjatic S, Bajorin DF, Rosenberg J, Leach S, et al. Abstract IA31: Measuring the emergence of non-self in tumors Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Ia31 |
0.32 |
|
| 2019 |
Walasek A, Wankel B, Almassi N, Teo MY, Funt S, Schultz N, Dalbagni G, Hu W, Al-Ahmadie H, Furberg-Barnes H, Petruzella S, Bajorin D, Rosenberg J, Iyer G, Bochner B, et al. Mp63-13 Next-Generation Sequencing Reveals Genomic Differences Between Male And Female Patients With Urothelial Carcinoma The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556856.02737.89 |
0.316 |
|
| 2019 |
Almassi N, Pietzak E, Funt S, Walasek A, Schultz N, Dalbagni G, Bochner B, Al-Ahmadie H, Teo MY, Bajorin D, Rosenberg J, Iyer G, Solit D. Pd47-05 Prevalence Of Actionable Genomic Alterations And The Use Of Targeted Therapy In Metastatic Urothelial Carcinoma The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556761.38994.Ea |
0.34 |
|
| 2019 |
Almassi N, Cha E, Vertosick E, Huang C, Wong N, Dason S, McPherson V, Dean L, Benfante N, Sjoberg D, Bajorin D, Rosenberg J, Dalbagni G, Vickers A, Bochner B. Pd47-04 Surgical And Oncologic Outcomes In Patients Undergoing Radical Cystectomy From 1995-2015: The Memorial Sloan Kettering Experience The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556760.31371.D5 |
0.327 |
|
| 2019 |
Almassi N, Pietzak E, Schultz N, Walasek A, Al-Ahmadie H, Teo MY, Funt S, Bajorin D, Rosenberg J, Iyer G, Dalbagni G, Bochner B, Solit D. Pd47-03 Characterizing The Landscape Of Actionable Genomic Alterations To Identify Opportunities For Targeted Therapy Trials In Patients With Localized Bladder Cancer The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556759.93252.81 |
0.366 |
|
| 2019 |
Walasek A, Almassi N, McPherson V, Dason S, Benfante N, Klein T, Berger M, Schultz N, Dalbagni G, Bajorin D, Rosenberg J, Al-Ahmadie H, Bochner B, Solit D, Iyer G, et al. Mp43-05 The Landscape Of Clinically Actionable Genomic Alterations In Patients With Bacille Calmette-Guerin (Bcg) Unresponsive Bladder Cancer: Towards Targeted Therapy In Non-Muscle Invasive Bladder Cancer The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556228.42539.Dd |
0.4 |
|
| 2018 |
Hurst C, Rosenberg J, Knowles M. SnapShot: Bladder Cancer. Cancer Cell. 34: 350. PMID 30107181 DOI: 10.1016/J.Ccell.2018.07.013 |
0.396 |
|
| 2018 |
Isharwal S, Audenet F, Drill E, Ostrovnaya I, Pietzak E, Al-Ahmadie H, Cha E, Donahue T, Teo MY, Funt S, Arcila M, Berger M, Rosenberg J, Bajorin D, Dalbagni G, et al. Mp54-04 Next Generation Sequencing Of Urothelial Bladder Cancer: Memorial Sloan Kettering Cancer Center Experience In 454 Patients The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1695 |
0.346 |
|
| 2018 |
Abbosh P, Liu D, Ibragimova I, Rosenberg J, Ford J, El-Deiry W, Parker D, Geynisman D, Alpaugh RK, Cairns P, Kutikov A, Van Allen E, Plimack E. MP41-04 URINARY CORRELATES OF PATHOLOGIC COMPLETE RESPONSE IN BLADDER CANCER PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1291 |
0.376 |
|
| 2017 |
Mouw K, Lazaro J, Damish A, Reznichenko E, Frazier Z, Liu D, Kim J, Polak P, Garraway L, Getz G, Rosenberg J, Allen EV, D'Andrea A. Abstract PR18: Somatic ERCC2 mutations, nucleotide excision repair (NER) function, and cisplatin response in muscle-invasive bladder cancer (MIBC) Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-Pr18 |
0.349 |
|
| 2017 |
Pandha H, Harrington K, Ralph C, Melcher A, Gupta S, Akerley W, Sandborn RE, Rudin C, Rosenberg J, Kaufman D, Schmidt E, Grose M, Shafren DR. Abstract CT115: Phase 1bKEYNOTE 200 (STORM study):A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct115 |
0.371 |
|
| 2017 |
Li Q, Bell A, Jordan E, Gao S, Ma J, Pietzak E, Dalbagni G, Bochner B, Rosenberg J, Bajorin D, Solit D, Riaz N, Iyer G. Mp98-04 Defective Ercc2 Confers Increased Cisplatin And Ionizing Radiation Sensitivity In Bladder Cancer Cells The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.3069 |
0.302 |
|
| 2017 |
Abbosh P, Liu D, Choid W, El-Deiry W, Rosenberg J, McConkey D, Plimack E, Van Allen E. MP88-11 IMMUNE CORRELATES OF PATHOLOGIC RESPONSE IN BLADDER CANCER PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2736 |
0.356 |
|
| 2017 |
Pietzak E, Cha E, Bagrodia A, Drill E, Iyer G, Baez P, Isharwal S, Li Q, Zehir A, Arcila M, Berger M, Schultz N, Ostrovnaya I, Rosenberg J, Bajorin D, et al. Pd48-11 Next Generation Sequencing Of Non-Muscle Invasive Bladder Cancer Reveals Potential Biomarkers And Rational Therapeutic Targets The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2359 |
0.373 |
|
| 2017 |
Isharwal S, Audenet F, Pietzak E, Cha E, Iyer G, Zehir A, Taylor B, Berger M, Tickoo S, Reuter V, Rosenberg J, Bajorin D, Dalbagni G, Bochner B, Solit D, et al. Mp65-15 Comparison Of Genomic Alterations In Bladder Urothelial Tumors With And Without Telomerase Reverse Transcriptase Promoter Mutation Using A Next-Generation Sequencing Assay The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2009 |
0.316 |
|
| 2017 |
Pietzak E, Bagrodia A, Al-Ahmadie H, Herr H, Zabor E, Barron D, Li Q, Audenet F, Funt S, Zehir A, Arcila M, Baez P, Berger M, Schultz N, Solit D, ... ... Rosenberg J, et al. Mp58-02 Genomic Differences Between “Primary” And “Secondary” Muscle Invasive Bladder Cancer: Implications For Neoadjuvant Chemotherapy The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1797 |
0.381 |
|
| 2017 |
Isharwal S, Huang H, Nanjangud G, Audenet F, Chen Y, Gopalan A, Fine S, Tickoo S, Iyer G, Rosenberg J, Bajorin D, Herr H, Donat M, Dalbagni G, Bochner B, et al. Mp48-03 Intratumoral Heterogeneity Of Erbb2 Amplification And Her2 Expression In Micropapillary Urothelial Carcinoma The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1484 |
0.304 |
|
| 2016 |
Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JM, Robinson B, Elemento O, Sboner A, Beltran H, Demichelis F, Rubin MA. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature Genetics. PMID 27749842 DOI: 10.1038/Ng.3692 |
0.367 |
|
| 2016 |
Mullane SA, Werner L, Rosenberg J, Signoretti S, Callea M, Choueiri TK, Freeman GJ, Bellmunt J. Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Scientific Reports. 6: 27702. PMID 27283319 DOI: 10.1038/Srep27702 |
0.312 |
|
| 2016 |
Sharma P, Bono P, Kim JW, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, Braud FGD, Morse MA, Le DT, Jaeger D, Chan E, Harbison CT, Lin C, Tschaika M, ... ... Rosenberg J, et al. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. Journal of Clinical Oncology. 34: 4501-4501. DOI: 10.1200/Jco.2016.34.15_Suppl.4501 |
0.374 |
|
| 2016 |
Althammer S, Steele K, Rebelatto M, Tan TH, Wiestler T, Schmidt G, Higgs B, Li X, Shi L, Jin X, Antal J, Gupta A, Ranade K, Binning G, Bellmunt J, ... ... Rosenberg J, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0191-4 |
0.49 |
|
| 2016 |
Bagrodia A, Sukhu R, Winer A, Vacchio M, Levy E, Lee B, Donahue T, Cha E, Assel M, Sjoberg D, Vickers A, Rosenberg J, Bajorin D, Dalbagni G, Bochner B. Mp06-01 Incidence And Impact Of Venous Thromboembolism In Radical Cystectomy Patients Undergoing Pre-Operative Chemotherapy For Muscle-Invasive Bladder Cancer The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2162 |
0.363 |
|
| 2016 |
Pietzak E, Cha E, Zabor E, Li Q, Solit D, Rosenberg J, Bajorin D, Bochner B, Herr H, Iyer G. Pi-01 Progression From Non-Muscle Invasive Bladder Cancer (Nmibc) To Muscle Invasion Is Associated With Lower Response Rates To Neoadjuvant Chemotherapy The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1206 |
0.343 |
|
| 2015 |
Mullane SA, Werner L, Guancial EA, Lis RT, Stack EC, Loda M, Kantoff PW, Choueiri TK, Rosenberg J, Bellmunt J. Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. PMID 26778300 DOI: 10.1016/J.Clgc.2015.12.029 |
0.316 |
|
| 2015 |
Bellmunt J, Werner L, Leow JJ, Mullane SA, Fay AP, Riester M, Van Hummelen P, Taplin ME, Choueiri TK, Van Allen E, Rosenberg J. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. Plos One. 10: e0124711. PMID 26039708 DOI: 10.1371/Journal.Pone.0124711 |
0.369 |
|
| 2015 |
Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, ... ... Rosenberg J, et al. HER2 as a target in invasive urothelial carcinoma. Cancer Medicine. 4: 844-852. PMID 25720673 DOI: 10.1002/Cam4.432 |
0.357 |
|
| 2015 |
Harshman L, Werner L, Wong YN, Yu E, Alva A, Crabb S, Powles T, Rosenberg J, Baniel J, Vaishampayan U, Berthold D, Ladoire S, Hussain S, Milowsky M, Agarwal N, et al. 2619 Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC) European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31437-X |
0.339 |
|
| 2015 |
Cha E, Sfakianos J, Scott S, Murugan P, Iyer G, Shah R, Bagrodia A, Desai N, Bajorin D, Rosenberg J, Berger M, Al-Ahmadie H, Bochner B, Coleman J, Solit D. Mp36-12 Clonality Of Bladder Tumors Following Radical Nephroureterectomy – Against The Field Defect Hypothesis The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.740 |
0.343 |
|
| 2014 |
Cha E, Sfakianos J, Al-Ahmadie H, Scott S, Kim P, Iyer G, Bajorin D, Rosenberg J, Berger M, Bochner B, Solit D. Mp21-19 Branched Evolution And Intratumor Heterogeneity Of Urothelial Carcinoma Of The Bladder The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.847 |
0.328 |
|
| 2013 |
Chekaluk Y, Wu CL, Rosenberg J, Riester M, Dai Q, Lin S, Guo Y, McDougal WS, Kwiatkowski DJ. Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. Plos One. 8: e60927. PMID 23593348 DOI: 10.1371/Journal.Pone.0060927 |
0.385 |
|
| 2013 |
Galsky MD, Hendricks R, Svatek R, Bangs R, Hoffman-Censits J, Clement J, Dreicer R, Guancial E, Hahn N, Lerner SP, O'Donnell PH, Quale DZ, Siefker-Radtke A, Shipley W, Sonpavde G, ... ... Rosenberg J, et al. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 119: 1994-8. PMID 23456777 DOI: 10.1002/Cncr.27973 |
0.35 |
|
| 2013 |
Bhatt AS, Pedamallu CS, Duke F, Jung J, Freeman SS, Cherniak A, Park R, Kim J, Kwiatkowski D, Rosenberg J, Meyerson M. Abstract 4149: Transcriptomic and pathogen analysis in bladder cancer primary tumor and metastasis pairs. Cancer Research. 73: 4149-4149. DOI: 10.1158/1538-7445.Am2013-4149 |
0.429 |
|
| 2013 |
Majumdar S, Gong E, Vizio DD, Dreyfuss J, DeGraff D, Hager M, Park P, Bellmunt J, Matusik R, Rosenberg J, Adam R. Abstract 4066: Loss of Sh3gl2/endophilin A1 is an early event in urothelial carcinoma that regulates malignant behavior. Cancer Research. 73: 4066-4066. DOI: 10.1158/1538-7445.Am2013-4066 |
0.371 |
|
| 2011 |
Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2432-8. PMID 21555688 DOI: 10.1200/Jco.2011.34.8433 |
0.346 |
|
| 2011 |
Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy The Lancet Oncology. 12: 211-214. PMID 21376284 DOI: 10.1016/S1470-2045(10)70275-8 |
0.349 |
|
| Show low-probability matches. |